Leader Nasal Decongestant

Description

Leader Original Nasal Spray is a nasal decongestant formulation containing 0.05% oxymetazoline hydrochloride. It is designed for use as a 12-hour nasal mist, providing effective relief from nasal congestion. The product is packaged in a 1/2 fluid ounce (15 mL) container. The National Drug Code (NDC) for this product is 70000-0676-1.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, sinusitis, and upper respiratory allergies. It acts by shrinking swollen nasal membranes, thereby facilitating easier breathing.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 6 to under 12 years of age, when administered under adult supervision, may receive 2 or 3 sprays in each nostril. Dosing should not exceed every 10 to 12 hours, and it is important to limit the total number of doses to a maximum of 2 in any 24-hour period.

For children under 6 years of age, it is recommended to consult a doctor prior to administration.

To properly administer the spray, the healthcare professional should instruct the patient to squeeze the bottle quickly and firmly. It is essential that the patient does not tilt their head backwards while spraying. After use, the nozzle should be wiped clean to maintain hygiene and prevent blockage.

Contraindications

Use is contraindicated in the following situations:

• Use is not recommended for more than three consecutive days due to the risk of nasal congestion recurrence or worsening.

• Administration should not exceed the directed dosage to prevent potential adverse effects.

• The product should not be used by multiple individuals from the same container to avoid the risk of infection transmission.

Warnings and Precautions

If ingestion occurs, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately. Prompt action is crucial in such situations to ensure patient safety.

Healthcare professionals should advise patients to discontinue use and consult a physician if symptoms persist. This precaution is essential to address any potential adverse effects or complications that may arise during treatment. Regular monitoring and assessment of the patient's condition are recommended to ensure the effectiveness of the therapy and to mitigate any risks associated with continued use.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. In clinical practice, it is important to monitor for serious reactions, particularly in individuals with pre-existing conditions.

Patients are advised to stop using the medication and consult a doctor if symptoms persist. Additionally, it is recommended that patients seek medical advice before using this product if they have a history of heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

These precautions are essential to ensure the safe use of the medication and to mitigate any risks associated with its administration.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions between the drug and laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Leader Nasal Decongestant (oxymetazoline hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important to note that the total dosage should not exceed 2 doses within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. It is essential for women of childbearing potential to discuss their individual circumstances with their healthcare provider to weigh the benefits and risks associated with the use of this medication during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there are no specific considerations or precautions mentioned concerning lactation. Therefore, healthcare professionals may consider the use of this product in nursing mothers without specific concerns related to breastfeeding.

Renal Impairment

Patients with renal impairment may not have specific information regarding dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and individualized patient assessment. Regular monitoring of renal function is advisable to ensure patient safety and therapeutic efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Additionally, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management strategies tailored to the substance involved in the overdose. Continuous monitoring and supportive care remain the cornerstones of effective management in such scenarios.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to adhere strictly to the recommended dosage and duration of use, emphasizing that the product should not be used for more than three days. Patients should be informed that exceeding the directed use may lead to a recurrence or worsening of nasal congestion.

It is important for healthcare providers to discuss potential temporary discomforts that may arise from using the product, including sensations of burning, stinging, sneezing, or an increase in nasal discharge. Patients should be made aware that these effects are generally transient but may be concerning.

Additionally, healthcare providers should caution patients against sharing the container with others, as this practice may facilitate the spread of infection. Ensuring that patients understand these key points will help promote safe and effective use of the product.

Storage and Handling

The product is supplied in packaging that includes specific NDC numbers, which should be referenced for identification. It is essential to store the product at a temperature range of 20° to 25°C (68° to 77°F) to maintain its integrity and efficacy.

Healthcare professionals are advised to retain the carton for future reference regarding the full labeling information, ensuring that all necessary details are readily accessible for proper handling and administration.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Leader Nasal Decongestant, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)